ClinicalTrials.gg
Not yet recruitingNCT07827703Updated Sep 23, 2026

Effects of Digital Detox on Mental Health in Young Adults

An interventional study of App-based smartphone screen time restriction program in Anxiety Symptoms, Screen Time and Depressive Symptoms, sponsored by University of Bergen. Not yet recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Bergen · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether a short, self-guided program for cutting down smartphone screen time can reduce symptoms of depression in young adults. It includes students in Oslo, Norway, who have applied for help at the student mental health service (SiO Mental Health).

The main questions it aims to answer are:

  • Does a 2-week screen time reduction program reduce symptoms of depression?
  • Does it reduce symptoms of anxiety?
  • Can a simple, widely available phone app reduce screen time, and does the reduction last?

Researchers will compare students who start the program right away with students who continue their usual care for 2 weeks and receive the same program afterwards. Participants are placed in one of the two groups by chance, like flipping a coin.

Participants will:

  • Answer questionnaires about depression and anxiety symptoms at the start and again after 2 weeks
  • Upload screenshots of the Screen Time summary on their iPhone at the start, after 2 weeks, and after 12 weeks
  • Install an app that blocks the apps they find most distracting and keep it active for 2 weeks, if they are placed in the program group
  • Take part entirely online, with no clinic visits and no contact with the study team
02

Conditions studied

  • Anxiety Symptoms
  • Screen Time
  • Depressive Symptoms

Browse trials for

03

In context

Depression Reclassified

8,577 studies on the registry are indexed under Depression; 1,720 are open to participants now.

This study's planned enrollment of 200 is above the median of 81 across 7,063 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

University of Bergen is the lead sponsor of 143 studies on the registry; 19 are open to participants now.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has applied for care at SiO Mental Health, the student mental health service in Oslo, and has received the service's response to the application
  • Owns an iPhone (the screen time restriction tool requires iOS)
  • Able to understand written Norwegian
  • Provides

Exclusion criteria

Exclusion Criteria:

- None

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Screen time reduction

    Behavioral: App-based smartphone screen time restriction program

  • No intervention
    Care as usual

Interventions

  • BehavioralApp-based smartphone screen time restriction program

    Two-week self-guided use of an iOS screen time restriction app. Participants block their most distracting apps, with notifications disabled. Unlocking requires a 30-second delay, allows 10 minutes of access, then a 5-minute cooldown.

06

What researchers measure

Primary outcomes

  1. Symptoms of depression (PHQ-9)

    Patient Health Questionnaire-9, range 0 to 27, higher scores indicate more depressive symptoms.

    Time frame: From enrollment to the end of intervention at 2 weeks

Secondary outcomes

  1. Symptoms of anxiety (GAD-7)

    Generalized Anxiety Disorder-7, range 0 to 21, higher scores indicate more anxiety symptoms.

    Time frame: From enrollment to the end of intervention at 2 weeks

  2. Total smartphone screen time

    Time frame: 2 weeks and 12 weeks after randomization

  3. Smartphone screen time by app category

    Time frame: 2 weeks and 12 weeks after randomization

  4. Number of daily smartphone pickups

    Time frame: 2 weeks and 12 weeks after randomization

Other outcomes

  1. Self-reported changes in daily functioning and well-being

    Twelve single-item questions on perceived change over the past 2 weeks, each answered on a 5-point scale from 1 (much less than usual) to 5 (much more than usual). The domains are sleep, time spent with others, physical activity, time on other screens (computer, tablet), loneliness, satisfaction with oneself, rumination on negative thoughts, feeling of missing out, stress, ability to concentrate, satisfaction with own study effort, and getting done what one plans. Higher scores indicate more of the attribute than usual. Whether a higher score represents a better outcome depends on the domain.

    Time frame: 2 weeks

  2. Adherence to the screen time restriction tool

    Self-reported proportion of the 2-week period with the blocking rule kept active, answered on a 5-level ordinal scale: all of the time, most of the time, part of the time, little of the time, none. Higher levels indicate greater adherence. Reported by the intervention group.

    Time frame: 2 weeks

  3. Perceived usefulness and burden of the tool

    Perceived usefulness of the tool for reducing screen time and perceived burden in everyday life, each answered on a 5-point scale from 1 (not at all) to 5 (to a very great extent), and a single question on intention to continue use (yes, no, do not know). Higher usefulness indicates a better outcome and higher burden a worse outcome. Reported by the intervention group at 2 weeks and by both groups at 12 weeks.

    Time frame: 2 weeks and 12 weeks

07

Study locations

1 site
  • Studentsamskipnaden i Oslo
    Oslo, Norway
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data underlying the published results.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: After publication of the primary results.

Access criteria: Upon request to the principal investigator, under a data sharing agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for May 2027, 8 months later.

Of 3,468 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 8 months is below that.

Counting every sponsor, half of 3,566 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 18, 2026
StartEst.
Sep 21, 2026
Primary completionEst.
May 2027
CompletionEst.
Aug 2027
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07827703
Collaborators
Studentsamskipnaden i Oslo (SiO)
Responsible party
Sponsor
First posted
Sep 18, 2026
Start date
Sep 21, 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 23, 2026

Study contacts

Thomas Mildestvedt, Professor
Contact
thomas.mildestvedt@uib.no
+47 55586163
Thomas Mildestvedt, Professor
principal investigator · University of Bergen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion